Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Aug 5;99(3):551-2.
doi: 10.1038/sj.bjc.6604451. Epub 2008 Jul 1.

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

F Di Fiore, F Charbonnier, B Lefebure, M Laurent, F Le Pessot, P Michel, T Frebourg
Comment

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

F Di Fiore et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Detection of methylated RASSF2A promoter in the primary tumour (T), liver metastases (M) and plasma (P) from patients 1 and 2. For patient 2, T1 and T2 correspond to the right and left colon adenocarcinoma, respectively. Genomic DNA was modified by bisulphite treatment and amplified with primers specific of the methylated RASSF2A promoter. M, molecular marker; Un, unmethylated DNA used as a negative control; Met, methylated DNA, used as a positive control. The arrows indicate the 110 bp amplified product (A). Detection of a KRAS mutation in the plasma from patient 1. Two independent real-time PCRs were performed from DNA extracted from plasma, in the presence and in the absence of a PNA specific of the wild-type KRAS sequence. The presence of mutant DNA within the sample is detected by a significant shift towards lower values of the cycle threshold (Ct) when the PNA is added to the reaction. The upper and lower panels correspond to the sequences of the amplified products obtained in the absence and presence of the PNA, respectively. In the presence of the PNA, only the mutant allele is amplified. The sequences correspond to the antisense strand, the box marks codon 12 and the arrows the c.35G>C mutation (B).
See this image and copyright information in PMC

Comment on

References

    1. Amado GR, Wolf M, Peeters M, Van Cutsem E, Siena S, Freedman DJ, Juan T, Sikorski R, Suggs S, Radinsky S, Patterson SD, Chang DD (2008) Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634 - PubMed
    1. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643–2648 - PubMed
    1. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508–515 - PubMed
    1. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166–1169 - PMC - PubMed
    1. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139–1145 - PMC - PubMed